BioStem director converts 7,671 RSUs to shares

BioStem Technologies, Inc. (BSEM) director Steven D. Sonenreich reported the vesting and conversion of 7,671 Restricted Stock Units into 7,671 shares of common stock on August 27, 2026.

Rhea-AI Filing Summary

BioStem Technologies, Inc. (BSEM) director Steven D. Sonenreich reported the vesting and conversion of 7,671 Restricted Stock Units into 7,671 shares of common stock on August 27, 2026. Each RSU represented a contingent right to receive one common share. Following the transaction, he directly held 7,671 shares of common stock and no remaining RSUs from this grant.

Insider Trade Summary

7,671 shares exercised/converted

Exercise 2 txns

Insider SONENREICH STEVEN D

Role Director

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units F1, F2	7,671	$0.00	$0.00
Exercise	Common Stock	7,671	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 0 contracts (Direct); Common Stock — 7,671 shares (Direct)

Footnotes (2)

1. F1. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
2. F2. These restricted stock units vested on August 27, 2026.

Key Figures

Restricted Stock Units exercised: 7,671 units Common Stock acquired from RSU conversion: 7,671 shares Common Stock holdings after transaction: 7,671 shares +3 more

6 metrics

Restricted Stock Units exercised 7,671 units RSUs converted into common stock on August 27, 2026

Common Stock acquired from RSU conversion 7,671 shares Shares received upon RSU exercise on August 27, 2026

Common Stock holdings after transaction 7,671 shares Direct ownership reported following the August 27, 2026 transaction

RSUs remaining after conversion 0 units RSU position from this grant after August 27, 2026 vesting

Exercise price per share $0.00 per share Reported for the RSU-to-common-stock conversion on August 27, 2026

Exercise or conversion of derivative security 1 transaction Code M event converting RSUs into common stock

Key Terms

Restricted Stock Units, contingent right, vested, Exercise or conversion of derivative security

4 terms

Restricted Stock Units financial

"Each restricted stock unit represents a contingent right to receive one share"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

contingent right financial

"represents a contingent right to receive one share of the issuer's"

vested financial

"These restricted stock units vested on August 27, 2026."

Exercise or conversion of derivative security financial

"transaction_code_description":"Exercise or conversion of derivative security"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did BioStem Technologies (BSEM) disclose in this Form 4?

The filing reports that director Steven D. Sonenreich exercised and converted 7,671 Restricted Stock Units into 7,671 shares of BioStem Technologies common stock on August 27, 2026, at a reported exercise price of $0.00 per share.

How many shares does the BioStem Technologies (BSEM) director hold after the transaction?

After the reported transaction, Steven D. Sonenreich directly holds 7,671 shares of BioStem Technologies common stock. The related 7,671 Restricted Stock Units were fully converted, leaving 0 RSUs from this grant outstanding.

What happened to the Restricted Stock Units reported for BSEM on August 27, 2026?

On August 27, 2026, 7,671 Restricted Stock Units vested and were converted into 7,671 shares of common stock. The RSU position went to 0 following this exercise and conversion event.

What does each Restricted Stock Unit represent in the BSEM Form 4 filing?

Each Restricted Stock Unit represents a contingent right to receive one share of BioStem Technologies common stock. Upon vesting, the RSUs are settled in common shares on a one-for-one basis, as disclosed in the footnotes.

Was the BioStem Technologies (BSEM) Form 4 transaction under a Rule 10b5-1 plan?

No. The filing’s Rule 10b5-1 checkbox is not affirmed (aff_10b5_one is false), and the footnotes do not state that the transaction was executed pursuant to a Rule 10b5-1 trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/28/2026 - 04:15 PM EDT Accepted by SEC EDGAR 08/28/2026 - 04:15 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SONENREICH STEVEN D

(Last) (First) (Middle)

C/O BIOSTEM TECHNOLOGIES, INC.

2836 CENTER PORT CIRCLE

(Street)

POMPANO BEACH FLORIDA 33064

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BioStem Technologies, Inc. [ BSEM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/27/2026		M		7,671	A	$0.00	7,671	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	08/27/2026		M			7,671	(2)	(2)	Common Stock	7,671	$0.00	0	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

2. These restricted stock units vested on August 27, 2026.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Katherine Gorrell, Attorney-in-Fact	08/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)